FDA Approves Jivi for Patients Aged 7 Years and Older with Hemophilia A

FDA approves Jivi for patients aged 7 years and older with hemophilia A

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.

FDA Approves Retifanlimab-dlwr as First-Line Treatment for Advanced Anal Cancer

The U.S. Food and Drug Administration (FDA) has granted […]

FDA approves Incyte’s new anal cancer treatment - Pharmafile

The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). Zynyz has also been approved as a monotherapy for patients who have progressed on or are intolerant to platinum-based chemotherapy. The drug […] The post FDA approves Incyte’s new anal…